Stefan Schönland
Schönland, Stefan 1969-
VIAF ID: 62428767 (Personal)
Permalink: http://viaf.org/viaf/62428767
Preferred Forms
- 100 1 _ ‡a Schönland, Stefan ‡d 1969-
- 100 0 _ ‡a Stefan Schönland
4xx's: Alternate Name Forms (9)
5xx's: Related Names (2)
Works
Title | Sources |
---|---|
Amyloid in endomyocardial biopsies. | |
Association of antigen-specific T-cell responses with antigen expression and immunoparalysis in multiple myeloma. | |
CD4+CD25highCD127low regulatory T cells in peripheral blood are not an independent factor for chronic graft-versus-host disease after allogeneic stem cell transplantation. | |
Cerebral amyloid angiopathy--an underdiagnosed entity in younger adults with lobar intracerebral hemorrhage? | |
[Chronic inflammation and AA amyloidosis] | |
Common Fibril Structures Imply Systemically Conserved Protein Misfolding Pathways In Vivo. | |
Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients. | |
Cryo-EM reveals structural breaks in a patientderived amyloid fibril from systemic AL amyloidosis | |
[Current diagnostic and therapy of light chain amyloidosis] | |
Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. | |
[Diagnostic procedures in the suspected presence of a blood cell dyscrasia]. | |
Diagnostic work up of an adult female patient with systemic AA amyloidosis revealing the cause of infantile mental retardation. | |
Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell-dyscrasia effect". | |
Doxycycline in ATTRY69H (p.ATTRY89H) amyloidosis with predominant leptomeningeal manifestation. | |
Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice. | |
Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis. | |
Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. | |
Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis | |
Flow in a fibril-forming disease | |
Funktionelle Analyse dominant negativer Mutanten der onkogenen Rezeptortyrosinkinase Xmrk von Yiphophorus | |
Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone | |
Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts. | |
Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene | |
High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study | |
Homeostatic control of T-cell generation in neonates | |
Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation | |
Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). | |
Immunoglobulin light-chain amyloidosis shares genetic susceptibility with multiple myeloma. | |
Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. | |
The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison | |
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT | |
Incremental value of cardiac magnetic resonance for the evaluation of cardiac tumors in adults: experience of a high volume tertiary cardiology centre | |
Modified body mass index and time interval between diagnosis and operation affect survival after liver transplantation for hereditary amyloidosis: a single-center analysis. | |
Mutational landscape reflects the biological continuum of plasma cell dyscrasias | |
Myocardial contraction fraction derived from cardiovascular magnetic resonance cine images-reference values and performance in patients with heart failure and left ventricular hypertrophy | |
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes | |
A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis | |
Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis | |
P957: Carfilzomib, lenalidomide, dexamethasone followed by a second auto-HCT is an effective strategy in first relapse multiple myeloma: a study of the chronic malignancies working party of EBMT | |
Polymorphism of Amyloid Fibrils In Vivo. | |
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. | |
Potential therapeutic targets in plasma cell disorders: A flow cytometry study. | |
Premature telomeric loss in rheumatoid arthritis is genetically determined and involves both myeloid and lymphoid cell lineages. | |
Prevalence of germline mutations in the TTR gene in a consecutive series of surgical pathology specimens with ATTR amyloid. | |
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study | |
Prognostic significance of semiautomatic quantification of left ventricular long axis shortening in systemic light-chain amyloidosis. | |
Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. | |
Rapid assessment of longitudinal systolic left ventricular function using speckle tracking of the mitral annulus. | |
Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis | |
Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience | |
Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation | |
Reply to S. Girnius et al. | |
Respiratory muscle weakness and inefficient ventilation in heart failure due to light-chain amyloidosis | |
Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances. | |
Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis | |
Risk factors for AA amyloidosis in Germany | |
Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation. | |
[Risk stratification and treatment of cardiac amyloidoses]. | |
Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM | |
Sjögren's syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity? | |
Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis | |
Solid state NMR assignments of a human λ-III immunoglobulin light chain amyloid fibril | |
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting). | |
Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools. | |
[Systemic light chain amyloidosis - molecular basis and clinical perspectives] | |
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. | |
Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting. | |
Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years |